Abiosciences offers an end-to-end single-cell and spatial solution from experiments to key bioinformatics insights.
New targets and biomarkers can be discovered based on precise cell type annotation, a metadata analysis platform, and single-cell techniques.
Using our tools and deep-rooted knowledge of single-cell sequencing, we have developed proprietary drug targets that can be licensed, accelerating your drug discovery process and lowering overall costs.
We invite interested partners to license or co-develop therapeutic leads from our array of validated therapeutic targets.